Cincinnati.Com
NKY.COM  |  ENQUIRER  |  CIN WEEKLY  |  Classifieds  |  Cars  |  Homes  |  Jobs  |  Help
Currently:
80°F
Mostly Sunny
Weather | Traffic
The Enquirer
HOME
NEWS
ENTERTAINMENT
SPORTS
REDS
BENGALS
LOCAL GUIDE
MULTIMEDIA
ARCHIVES
SEARCH
 
 TODAY'S ENQUIRER 
 Front Page 
 Local News 
 Sports 
-- Business 
 Editorials 
 Tempo 
 Home Style 
 Travel 
 Health 
 Technology 
 Weather 
 Back Issues 
 Search 
 Subscribe 

 SPORTS 
 Bearcats 
 Bengals 
 High School 
 Reds 
 Xavier 

 VIEWPOINTS 
 Jim Borgman 
 Columnists 
 Readers' views 

 ENTERTAINMENT 
 Movies 
 Dining 
 Horoscopes 
 Lottery Results 
 Local Events 
 Video Games 

 CINCINNATI.COM 
 Giveaways 
 Maps/Directions 
 Send an E-Postcard 
 Coupons 
 Visitor's Guide 
 Web Directory 

 CLASSIFIEDS 
 Jobs 
 Cars 
 Homes 
 General 
 Place an ad 

 HELP 
 Feedback 
 Subscribe 
 Search 
 Newsroom Directory 



 
Wednesday, January 28, 2004

Jurors in Stewart case hear opposite stories



By Erin McClam-
The Associated Press

NEW YORK - Martha Stewart sold stock based on "a secret tip" no one else had, then lied to save her reputation and fortune, a federal prosecutor told a jury Tuesday.

Stewart's lawyer insisted that the case was based on "speculation, surmise and guesswork."

The jury of eight women and four men listened to three hours of opening statements that outlined starkly different portrayals of Stewart's sale of almost 4,000 shares in the biotechnology company ImClone Systems on Dec. 27, 2001.

The government contends that Stewart was tipped that ImClone founder Sam Waksal was trying to dump his shares, then ordered her shares sold.

Assistant U.S. Attorney Karen Patton Seymour said Stewart then conspired with her stockbroker, Peter Bacanovic, to lie about the sale.

"The reason that Martha Stewart dumped her shares is because she was told a secret," Seymour said. "A secret tip that no other investors in ImClone had."

Lawyers for Stewart and Bacanovic aimed to convince jurors that the two defendants had done nothing out of the ordinary, arguing that they had decided six days before the ImClone sale to get rid of the stock if it fell to $60.

Waksal later admitted that he was tipped that federal regulators were about to issue a negative report on ImClone's only drug, the cancer treatment Erbitux. That report sent the stock plummeting. Waksal later pleaded guilty to securities fraud.




BUSINESS HEADLINES
Utility wants early 'thaw'
Viruses clog computers again
Ads face tough sell in future
Erpenbeck tries to avoid prison
Jurors in Stewart case hear opposite stories
Senate's pension bill due today
Condos, penthouses in developer's plan
Tristate summary
Business digest
O'Gara shares reach high
Finnan sought for hearing
Consumer outlook rises in January
Ranks thin in fourth month
Kraft to pare 6,000 jobs
Europe a tricky market for digital music

 

Latest Headline News
Updated Every 30 Minutes
BUSINESS NEWS

U.S. Rises in Auto Reliability Ratings

Congolese Shun Own Currency for Dollars

Delta Air Lines Posts $52M Profit in 3Q

Prepared Holiday Meals Up in Popularity

Christmas Returns to Wal-Mart Marketing


Cincinnati.Com
Search our site by keyword:  
Search also: News | Jobs | Homes | Cars | Classifieds | Obits | Coupons | Events | Dining
Movies/DVDs | Video Games | Hotels | Golf | Visitor's Guide | Maps/Directions | Yellow Pages

  CINCINNATI.COM  |  NKY.COM  |  ENQUIRER  |  CIN WEEKLY  |  Classifieds  |  Cars  |  Homes  |  Jobs  |  Help


Search | Questions/help | News tips | Letters to the editors | Subscribe
Newspaper advertising | Web advertising | Place a classified | Circulation

Copyright 1995-2007. The Cincinnati Enquirer, a Gannett Co. Inc. newspaper.
Use of this site signifies agreement to terms of service updated 12/19/2002.